London South East | The UK's favourite investor portal.

People taking notice now of a new market opening up for them in Europe,,,,,,,,all IMO RNS Number : 5616X Beximco Pharmaceuticals Ltd 11 February 2013 February 11, 2013 News Release Beximco Pharma Enters EU Market Beximco Pharmaceuticals Limited ("BPL" or "the Company"; AIM Symbol: BXP), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces that it has commenced export of Company products to Europe. Initially shipments of two ophthalmic products, Latanoprost and a combination of Latanoprost and Timolol, will be exported to Germany and Austria with other EU countries to follow. Latanoprost and Timolol are used to reduce the pressure inside the eye for people with open-angle glaucoma or intraocular hypertension (increased pressure in the eye). The Company expects to launch additional new products in the EU later this year. Managing Director of Beximco Pharma, Nazmul Hassan MP, commented: "Beximco has established a presence in a growing number of markets around the world. The Company is increasingly focused on penetrating large and highly regulated markets such as the EU and US, where the demand for generic products continues to rise. Beximco has developed high quality pharmaceutical facilities in Bangladesh, with a competitive cost structure for manufacturing and exporting generic drugs. This is a combination that is of increasing importance as governments strive to reduce healthcare costs without compromising on quality. We look forward to launching further products in Europe, the 2nd largest pharmaceutical market in the world with sales in excess of US$265 billion(1) , and providing patients with safe and affordable treatment options." Beximco Pharma is the largest exporter of pharmaceuticals in Bangladesh, the only company to win the National Export Trophy (Gold), the highest national accolade for export, a record four times. The Company currently has a global footprint in more than 50 countries. In addition to EU regulatory certification, Beximco Pharma has also received accreditations from TGA Australia, GCC (Gulf member states), and ANVISA (Brazil). The Company's ophthalmic facility is the only ophthalmic facility in Bangladesh accredited by the European and Australian drug regulatory authorities. Ends For further enquiries please contact: Beximco Pharma Nazmul Hassan MP, Managing Director Tel: +880 2 861 9151, ext.2080 Md. Asad Ullah, FCS, Executive Director & Company Secretary Tel; +880 2 8618220-1, Ext 1140 Libertas Capital Corporate Finance

Sorry for not completing previous post,,,,,but here it is Silverdell already has an impressive list of customers, predominantly blue-chip multi-national groups in power generation, oil and gas, chemicals and associated industries. But there is also a significant revenue stream from public sector work. As well as growing its capability as a supplier of high-hazard industrial maintenance and support services within a number of framework contracts, there are exciting opportunities in the pipeline, not least the decommissioning of first and second generation nuclear power stations, including continental Europe, where 150 plants are expected to be decommissioned over the next 15 years at an average cost of around £500m per plant. SHARE TIP SUMMARY: Profits last year were all but wiped out by exceptional and amortisation charges of £3.5m, much of which related to acquisition and restructuring costs. In fact, gross profits rose 27 per cent to £20.4m. You can see the growth potential when considering that since we first tipped the shares at 7.25p two years ago, the price has more than doubled, and yet the shares still trade on just 8 times forecast EPS. True, there is a modest dividend payout, but the shares only began to produce income last year and the payout is forecast to double in 2013. And given Silverdell’s established position in a market where much of the spending is non-discretionary, and the entry barriers are significant, profits and dividends look set to grow. Buy. SILVERDELL (SID) ORD PRICE: 17p MARKET VALUE: £53.2m TOUCH: 17-17.5p 12M HIGH: 18.1p LOW: 8.25p DIVIDEND YIELD: 2.4% PE RATIO: 8 NET ASSET VALUE*: 12p NET DEBT: 29% Year to 30 Sep Turnover (£m) Pre-tax profit (£m) Earnings per share (p) Dividend per share (p) 2009 59.5 -6.87 -7.30 nil 2010 56.7 1.83 0.50 nil 2011 59.7 2.46 1.10 nil 2012 82.5 0.53 0.00 0.18 2013* 133 9.30 2.10 0.40 % change +61 - - +122 Normal market size: 7,000 Market makers: 6 Beta: 0.45 Finncap estimates, underlying pre-tax profits and EPS not directly comparable. *Includes intangibles of £26m, or 8.4p per share

Topped up yesterday and today,,,,,,,,divi and this write up gives me a lot of confidence in SID IC BUY RECOMMENDATION 01-02-13 Silverdell offers undervalued growth Bull points •Asbestos removal a non-discretionary expense •Strong barriers to entry for hazardous waste treatment •Widening revenue stream •Profits rising sharply Bear points •Modest dividend •Exposure to cutbacks in new construction Silverdell shares offer the enticing opportunity to buy into a relatively defensive growth story on a single-digit PE ratio. While recessions come and go, the need to dispose of hazardous waste such as asbestos is a recurring theme. True, the stuff can't be used in new construction, but there is still around £17bn of asbestos removal work left in the UK. And this is one of the aspects of hazardous waste that Silverdell (SID) specialises in. Importantly, unlike other types of waste disposal, asbestos treatment and removal is a highly complex business, providing natural barriers for potential entrants. What's more, there are strict regulations governing the handling of asbestos, making its treatment a largely non-discretionary expense. And it is also worth pointing out that asbestos-related deaths remain the biggest work-related killer in the UK, claiming a life every two hours, and asbestos-related claims are expected to exceed £11bn over the next 40 years. However, Silverdell's range of services on offer expanded sharply last year with the acquisition of EDS, a specialist in dismantling and decommissioning. Silverdell can now offer an end-to-end decommissioning, dismantling and remediation service. The one-stop offering is already starting to pay off. Earlier this month, the group won a £12m order to decommission an oil-fired power station in Canada, adding to an order book that more than doubled last year to £219m, of which £97m is work scheduled for this year. And the group also has plans to build its consulting business not only in Canada but in Australia as well. Silverdell operates three divisions, of which remediation is the largest accounting for 47 per cent of underlying profits. This is where the group provides services that identify, treat and remove harmful substances. Decommissioning, which accounted for 22 per cent of last year's profits, includes the EDS operation that was bought at the end of the third quarter and involves activities such as recycling precious metals from factories. The consulting division provides environmental surveys, monitoring and project management services. Of course, no business is entirely immune from the effects of an economic downturn, and clearing potential building areas of hazardous waste has in some cases been put on hold until the climate improves. However, construction accounts for just 8 per cent of total remediation revenue. Silverdell already has an impressive list of customers, predominantly blue-c

Latest Share Chat

Member Info for clogheen

Followers

Following

Posts (Last 30 Days)

Posts (All Time)

Last Post

Member Since

Share Chat Post Distribution (Last 30 Days)

Activity Log (Last 30 Days)